Sanofi gets a lift from Boehringer and Xyzal

3 May 2017 - Deborah Wilkes

Archived

Acquiring Boehringer Ingelheim's Consumer Health Care business lifted worldwide sales at Sanofi Consumer Healthcare by 42.7% at constant exchange rates to EUR1.34 billion (USD1.46 billion) in the first quarter of 2017. Launching Xyzal Allergy 24HR (levocetirizine dihydrochloride) in the US contributed EUR43 million.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: